Man Group’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Man Group’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-182,000	Closed	-$424K	–	2506
2022 Q1	$424K	Buy	+182,000	New	+$568K	﹤0.01%	1636
2021 Q2	–	Sell	-159,775	Closed	-$1.32M	–	2142
2021 Q1	$1.32M	Buy	+159,775	New	+$1.69M	0.01%	1221
2018 Q4	–	Sell	-253,990	Closed	-$1.12M	–	2174
2018 Q3	$1.12M	Buy	+253,990	New	+$1.41M	﹤0.01%	1628
2018 Q2	–	Sell	-1,342,616	Closed	-$6.91M	–	2268
2018 Q1	$6.91M	Buy	+1,342,616	New	+$9.55M	0.03%	672

Other funds holding SRNE

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Man Group's SRNE Position: Q2 2022 in Review

Man Group sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2022, closing a stake of 182,000 shares — an estimated $424K sold.

Man Group first reported a position in SRNE in Q1 2018 and held it in 4 quarters. The position peaked at $6.91M in Q1 2018. 229 funds tracked by Wall St. Rank hold SRNE as of Q2 2022.

Man Group reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
Man Group sold 182,000 Sorrento Therapeutics, Inc. shares in Q2 2022, an estimated $424K.
Man Group first reported a position in Sorrento Therapeutics, Inc. in Q1 2018 and held it in 4 quarters.
Man Group's Sorrento Therapeutics, Inc. position peaked at $6.91M in Q1 2018.
229 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2022.

Based on Man Group's 13F filing for Q2 2022, filed 15 Aug 2022.